OKYO Pharma (Nasdaq: OKYO) highlights cash for NEPTUNE Phase 3
Rhea-AI Filing Summary
OKYO Pharma Limited filed its Annual Report on Form 20‑F for the fiscal year ended March 31, 2026 and highlighted stronger funding for its lead eye‑disease program.
The company raised approximately $25 million during the year, including a February 2026 public offering of about $22 million in gross proceeds, and reported cash and cash equivalents of approximately $20.6 million as of the end of March 2026. Management states that this cash provides resources to be fully funded through completion of NEPTUNE, a global Phase 3 pivotal trial of urcosimod in neuropathic corneal pain.
NEPTUNE is planned to start in the second half of 2026, enrolling around 111 patients in the US and Europe, randomized 2:1 to receive 0.05% urcosimod or placebo in a single‑dose regimen, and is designed, with FDA Type D feedback, as a potential registrational study.
Positive
- The company reports raising approximately $25 million during the fiscal year and holding about $20.6 million in cash and equivalents, which management says provides resources to be fully funded through completion of the NEPTUNE Phase 3 pivotal trial for urcosimod.
Negative
- None.
Key Figures
Key Terms
neuropathic corneal pain medical
Phase 3 pivotal trial medical
Type D meeting regulatory
ChemR23 G-protein-coupled-receptor medical
forward-looking statements regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What did OKYO (OKYO) disclose about its cash position as of March 31, 2026?
How much capital did OKYO (OKYO) raise during the fiscal year ended March 31, 2026?
What are the key design features of OKYO (OKYO)'s NEPTUNE Phase 3 trial?
When does OKYO (OKYO) plan to start the NEPTUNE Phase 3 trial for urcosimod?
What indication is OKYO (OKYO) targeting with its lead candidate urcosimod?
How does OKYO (OKYO) describe the regulatory feedback for the NEPTUNE study?
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
July 2026
Commission File Number: 001-41386
OKYO Pharma LTD
(Exact Name of Registrant as Specified in Its Charter)
9th Floor
107 Cheapside
London
EC2V 6DN
(Address of registrant’s principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K
On July 20, 2026, OKYO Pharma LTD (the “Company”) issued this 6K announcing the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SEC’s website and the Company’s investor relations page. In conjunction with the filing, the Company provided a positive corporate update on its financial strength and clinical momentum.
The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, This report on Form 6-K is hereby incorporated by reference into the Company’s Registration Statement on Form F-3 (Reg. No. 333-293145)
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| OKYO Pharma LTD | ||
| Date: July 20, 2026 | By: | /s/ Keeren Shah |
| Name: | Keeren Shah | |
| Title: | Chief Financial Officer | |
| 3 |
EXHIBIT INDEX
| Exhibit No. | Description | |
| 99.1 | News Announcement, dated July 20, 2026 |
| 4 |
Exhibit 99.1
OKYO Pharma Announces Filing of Annual Report with Strengthened
Cash Position and Accelerated Phase 3 Plans
London and New York, NY, July 20, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced the filing of its Annual Report on Form 20-F for the fiscal year ended March 31, 2026, with the U.S. Securities and Exchange Commission (SEC). The report is available on the SEC’s website and the Company’s investor relations page. In conjunction with the filing, the Company provided a positive corporate update on its financial strength and clinical momentum.
“We are pleased to announce the filing of our annual report, which reflects substantial progress across our operations,” said Keeren Shah, Chief Financial Officer of OKYO Pharma. “During the year we raised approximately $25 million, including the recent capital raise backed by renowned investment funds, which has strengthened our cash position provides us with ample financial resources to complete the NEPTUNE Phase 3 pivotal trial for urcosimod. This advances us toward potential registration, creating long-term value for patients and shareholders.”
Recent Capital Raise Backed by Renowned Investment Funds
OKYO Pharma successfully completed a public offering in February 2026 raising approximately $22 million in gross proceeds (including an overallotment), supported by strong participation from renowned investment funds and institutional investors. This capital infusion has significantly bolstered the Company’s balance sheet.
Robust Cash Position Enables Completion of Phase 3 Pivotal Trial
The strengthened financial position, with cash and cash equivalents of approximately $20.6 million as of end of March 2026, provides OKYO with the resources to be fully funded through the completion of the recently FDA-agreed global Phase 3 pivotal trial for its lead candidate urcosimod in NCP, positioning the Company for key upcoming milestones.
Overview of the NEPTUNE Clinical Trial
OKYO is advancing the NEPTUNE trial (Neuropathic Eye Pain Treatment with Urcosimod & Nerve Evaluation), a global Phase 3 pivotal study planned for initiation in the second half of 2026. The trial will enroll approximately 111 patients in the US and Europe, randomized 2:1 to receive 0.05% urcosimod or placebo in a single-dose regimen. Supported by positive FDA feedback from a Type D meeting, NEPTUNE is designed as a potential registrational study that could support an efficient single-trial approval pathway.
About Urcosimod
OKYO’s lead candidate, urcosimod, is a first-in-class, lipid-conjugated chemerin peptide agonist of the ChemR23 G-protein-coupled-receptor which is typically found on immune cells of the eye responsible for the ocular inflammatory response, as well as on neurons and glial cells in the dorsal root ganglion. Urcosimod has demonstrated ocular analgesic and anti-inflammatory pharmacologic activity through its dual mechanism of action, supporting its therapeutic potential to address the significant unmet medical need for patients with neuropathic corneal pain.
About OKYO Pharma
OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market. OKYO plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.
Forward-Looking Statements
Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company’s current expectations, estimates, and projections about its industry, its beliefs, and assumptions. Words such as ‘anticipates,’ ‘expects,’ ‘intends,’ ‘plans,’ ‘believes,’ ‘seeks,’ ‘estimates,’ and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company’s control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. These and additional risks and uncertainties are described more fully in the company’s filings with the SEC, including those factors identified as “Risk Factors” in our most recent Annual Report on Form 20-F, for the fiscal year ended March 31, 2026. The company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements, except as may be required by law.
For further information, please visit www.okyopharma.com.
For further inquiries:
OKYO Pharma Ltd
Paul Spencer
Business Development and Investor Relations
+44 (0) 207 495 2379
Email: info@okyopharma.com